ICYMI: SRP-9003 Study Shows Positive Results for Treating LGMD Type 2E
27707 / Pixabay

ICYMI: SRP-9003 Study Shows Positive Results for Treating LGMD Type 2E

  In a recent press release, biotechnology company Sarepta Therapeutics announced positive findings from their clinical trial studying SRP-9003 as a treatment for limb-girdle muscular dystrophy (LGMD) type 2E. This…

Continue Reading ICYMI: SRP-9003 Study Shows Positive Results for Treating LGMD Type 2E

This Journal Highlights Current Research on Neuromuscular Diseases (NMD)

In a Special Issue of the journal Disease Models and Mechanisms Highlights, James J. Dowling et al describes pediatric neuromuscular diseases as mostly genetic and affecting areas of the peripheral…

Continue Reading This Journal Highlights Current Research on Neuromuscular Diseases (NMD)
Close Menu